Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group.

Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530. Epub 2008 Mar 31.

2.

Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.

De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.

Minerva Cardioangiol. 2014 Dec;62(6):437-48. Epub 2014 Jul 16.

PMID:
25029569
3.

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.

Cochrane Database Syst Rev. 2014 Oct 23;(10):CD007744. doi: 10.1002/14651858.CD007744.pub2. Review.

PMID:
25340915
4.

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R.

J R Soc Med. 2006 Mar;99(3):132-40. Review.

5.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

PMID:
22386831
6.

Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.

Feng GS, Ma JL, Wong BC, Zhang L, Liu WD, Pan KF, Shen L, Zhang XD, Li J, Xia HH, Li JY, Lam SK, You WC.

World J Gastroenterol. 2008 Jul 28;14(28):4535-9.

8.

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.

Am J Cardiol. 2007 Jan 1;99(1):91-8. Epub 2006 Nov 10.

PMID:
17196469
9.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

10.
11.

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators.

Circulation. 2006 Sep 5;114(10):1028-35.

12.

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators.

N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.

13.

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.

PMID:
12914871
14.
16.

Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.

Kellner HL, Li C, Essex MN.

Curr Med Res Opin. 2012 Sep;28(9):1537-45. Epub 2012 Aug 16.

PMID:
22852870
17.
18.

C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.

20.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.

J Rheumatol. 2000 Aug;27(8):1876-83.

PMID:
10955327

Supplemental Content

Support Center